Biofrontera (BFRI) Expected to Post Quarterly Earnings on Wednesday

Biofrontera (NASDAQ:BFRI) is expected to be releasing its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.1050) per share and revenue of $9.50 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.29). The company had revenue of $10.08 million for the quarter, compared to analysts’ expectations of $10.25 million. Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%. On average, analysts expect Biofrontera to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biofrontera Stock Performance

Shares of BFRI opened at $1.22 on Wednesday. Biofrontera has a 1 year low of $0.55 and a 1 year high of $1.27. The stock has a market capitalization of $15.62 million, a PE ratio of -1.26 and a beta of 0.78. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.09 and a current ratio of 1.20. The stock has a 50-day simple moving average of $1.03 and a 200-day simple moving average of $0.96.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biofrontera stock. Geode Capital Management LLC increased its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the quarter. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Finally, Wall Street Zen upgraded Biofrontera to a “hold” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.